Safety and Efficacy of antiviral drugs against covid-19 infection: an updated systemic review

Atheer Majid Rashid Al-juhaishi; Noor D. Aziz

doi:10.55940/medphar20226

Authors

Atheer Majid Rashid Al-juhaishi Department of Clinical Pharmacy, College of Pharmacy/University of Karbala, Iraq.
Noor D. Aziz Department of Clinical Pharmacy, College of Pharmacy/University of Karbala, Iraq.

DOI:

https://doi.org/10.55940/medphar20226

Keywords:

SARS-CoV-2, antiviral potency, safety, Efficacy

Abstract

SARS-CoV-2 infection is an acute pneumonia attack caused by a largely-infectious, recently elicited, and murdered virus with global public health issues and economic problems. Many antiviral agents were tried to eradicate COVID-19 infections, and some showed significant benefits with minimal toxicity. Although other agents showed some acceptable efficacy, these agents were associated with serious adverse effects. In this regard, we conducted a systematic review of the literature to evaluate antiviral therapies that could help patients eliminate COVID-19.
To conduct this review, we used many search engines, including the electronic databases Science Direct, Google Scholar, PubMed, Scopus, and Web of Science, from Nov. 2020 to Apr. 2022. This research aims to evaluate the Efficacy and safety of antiviral agents that have been clinically tested against COVID-19 infection, with an emphasis on FDA-approved antiviral agents such as
remdesivir, Paxlovid, and molnupiravir to reduce the severity of COVID-19 infection and lower the mortality rate.